2022
Biomarkers of Chemotherapy-Induced Peripheral Neuropathy: Current Status and Future Directions
Rodwin RL, Siddiq NZ, Ehrlich BE, Lustberg MB. Biomarkers of Chemotherapy-Induced Peripheral Neuropathy: Current Status and Future Directions. Frontiers In Pain Research 2022, 3: 864910. PMID: 35360655, PMCID: PMC8963873, DOI: 10.3389/fpain.2022.864910.Peer-Reviewed Original ResearchPeripheral neuropathyChemotherapy-Induced Peripheral NeuropathyTreatment of CIPNMultiple chemotherapeutic agentsQuality of lifeImportant clinical toolCancer survivorsTherapeutic optionsCIPNClinical practicePreventative treatmentPromising biomarkerChemotherapeutic agentsClinical implicationsClinical toolCancer diagnosisBiomarkersNeuropathyStandardized objective measuresPatientsObjective measuresTreatmentRiskChemotherapyComplications
2021
A Case of Pheochromocytoma as a Subsequent Neoplasm in a Survivor of Childhood Embryonal Rhabdomyosarcoma
Rodwin RL, Janardan SK, Hofstatter EW, Kadan-Lottick NS. A Case of Pheochromocytoma as a Subsequent Neoplasm in a Survivor of Childhood Embryonal Rhabdomyosarcoma. Journal Of Pediatric Hematology/Oncology 2021, 44: e585-e588. PMID: 35200227, PMCID: PMC8873988, DOI: 10.1097/mph.0000000000002270.Peer-Reviewed Case Reports and Technical NotesConceptsChildhood embryonal rhabdomyosarcomaSubsequent neoplasmsEmbryonal rhabdomyosarcomaGenetic testingPathogenic variantsCase of pheochromocytomaChildhood cancer survivorsCancer predispositionClinical presentationCancer survivorsGenetic cancer predispositionClinical implicationsUncertain significanceNeoplasmsRhabdomyosarcomaSurvivorsPredispositionPheochromocytomaBladderTestingDeafnessVariantsWomen